PD-L1 inhibitory peptide TFA
Based on 1 Customer Validation
PD-L1 inhibitory peptide TFA is an inhibitor targeting the PD-1/PD-L1 interaction. PD-L1 inhibitory peptide TFA inhibits the PD-1-mediated apoptosis signaling pathway, maintains the survival and activity of T cells, activates the anti-tumor effect of cytotoxic T lymphocytes, and significantly improves the survival rate of mice in fungal sepsis models. PD-L1 inhibitory peptide TFA can be used for research on sepsis, breast cancer and other related diseases, as well as immunotherapy.
Para uso exclusivo en investigación. No vendemos a pacientes.
- Pureza : 99.81%
- Fòrmula: C96H135N21O23S.xC2HF3O2
- Peso molecular:1983.29 (free base)
-
Almacenamiento:
Sealed storage, away from moisture.
Powder -80°C, 2 years , -20°C, 1 year* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
Actividad biológica
Descripciòn
In Vitro
PD-L1 inhibitory peptide TFA binds to the natural PD-L1 interaction pocket on human PD-1 with a theoretical binding energy of -10.28 kJ[2].
PD-L1 inhibitory peptide TFA (0.024-120 μM) binds directly to recombinant human PD-1 with dose-dependent affinity, and competitively inhibits PD-L1 binding to PD-1 in a dose-dependent manner[2].
PD-L1 inhibitory peptide TFA (0.2984 μg/mL; 30 min pre-incubation, 6 h co-culture) blocks the PD-1/PD-L1 interaction in co-cultures of PD-L1-expressing CHO-K1 cells and PD-1-expressing Jurkat E6-1 cells with an EC50 of 0.2984 μg/mL[2].
PD-L1 inhibitory peptide TFA rescues Jurkat E6-1 cells and murine primary lymphocytes from PD-L1-induced apoptosis, reducing apoptotic signals by 25% in Jurkat cells and preserving primary lymphocyte viability without inducing T-cell death[2].
PD-L1 inhibitory peptide TFA (24 h) promotes a dose-dependent increase in active CD3+/CD45+/CD8+ T-cells in co-cultures of human PBMCs and MDA-MB-231 cells[2].
PD-L1 inhibitory peptide TFA (10 nM-11.6 μM; 24 h) at 11.6 μM rescues murine primary T-cells from apoptosis in co-culture with 4T1 cells, increases 4T1 cell death, and induces a significant, dose-dependent increase in Granzyme B production by CD3+/CD8+ T-cells[2].
PD-L1 inhibitory peptide TFA (0.2-12.5 μg/mL; 24 h) induces dose-dependent increases in IFNγ and dose-dependent decreases in IL-12p70 and IL-10 secretion by murine primary lymphocytes co-cultured with 4T1 cells, indicating enhanced T-cell activation and reduced inhibitory signaling[2].
PD-L1 inhibitory peptide TFA (30 μM; 30 min pre-treatment, 24 h co-culture) enhances Jurkat E6-1 cell infiltration into a 3D MDA-MB-231 tumor microenvironment, reduces Jurkat apoptosis, and induces greater MDA-MB-231 cell death than anti-PD-1 antibody treatment[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
-
Cell Line:Murine primary lymphocytes, 4T1 cells
-
Concentration:11.6 μM (EC50, apoptosis/cytotoxicity); 10 nM-10 μM (Granzyme B measurement)
-
Incubation Time:24 h co-culture
-
Result:Rescued primary T-cells from apoptosis and increased 4T1 cell death at 11.6 μM.
Induced a significant, dose-dependent increase in Granzyme B production by CD3+/CD8+ T-cells, exceeding levels seen with anti-PD-1 antibody treatment.
In Vivo
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:CD1 mice (six- to eight-week-old male; cecal ligation and puncture plus intravenous Candida albicans injection-induced sublethal polymicrobial sepsis)[1]
-
Dosage:3 mg/kg
-
Administration:s.c.; three times daily; Day 5 through Day 13 post-CLP
-
Result:Increased survival rate to 59.4% compared to 30.3% in control peptide-treated mice.
Showed statistically significant difference (p = 0.015).
Chemical Information
-
Appearance Solid
-
Peso molecular 1983.29 (free base)
-
Fòrmula C96H135N21O23S.xC2HF3O2
-
Color White to off-white
-
Sequence
Ac-Tyr-{NMe-Ala}-Asn-Pro-Dap-Leu-Hyp-Trp-Dab-Trp{CH2COOH}-{NMe-Nle}-{NMe-Nle}-Leu-Cys-Gly-{L-Propargylglycine} (thioether bridge:Tyr1-Cys15)
-
Envío
Room temperature in continental US; may vary elsewhere.
-
Almacenamiento
Sealed storage, away from moisture
Powder -80°C 2 years -20°C 1 year * In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
Solvente y solubilidad
In Vitro:
DMSO : 50 mg/mL (Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Protocolo
-
Apoptosis
Apoptosis, also called programmed cell death, is generally characterized by distinct morphological characteristics.
-
TUNEL staining for apoptotic DNA fragmentation
TUNEL staining detects DNA strand breaks by using terminal deoxynucleotidyl transferase to add labeled nucleotides to exposed 3′-OH DNA termini, generating either microscopic staining in fixed cells or tissue sections, or fluorescence/cytometric signal in cell suspensions. TUNEL positivity reflects DNA fragmentation but should not be interpreted alone as definitive apoptosis, because TUNEL can also label necrotic, autolytic, mechanically damaged, or DNA-repair-associated DNA breaks.
-
LPS-Induced Endotoxemia/Systemic Inflammation
Lipopolysaccharide (LPS)-induced endotoxemia is a widely used in vivo model of acute systemic inflammation in which LPS, a Gram-negative bacterial endotoxin, activates innate immune signaling primarily through TLR4, leading to rapid and transient induction of pro-inflammatory cytokines such as TNF-α, IL-6, and IL-1β in circulation and tissues. This cytokine surge is commonly used as a measurable readout of systemic inflammatory activation and immune dysregulation, and is typically assessed within hours after intraperitoneal LPS administration in mouse models of endotoxemia. The model captures key features of systemic inflammatory response syndrome, including cytokine release, immune cell activation, and downstream tissue responses, and has been used to evaluate anti-inflammatory interventions such as cytokine modulation, lipid mediators, and immune cell-targeting therapies.
-
Annexin V plus membrane-impermeant dye apoptosis staining
Annexin V-based apoptosis assays rely on the detection of phosphatidylserine (PS) externalization from the inner leaflet of the plasma membrane to the outer leaflet, an early biochemical hallmark of apoptosis. Fluorescently labeled Annexin V binds PS in a calcium-dependent manner, enabling identification of early apoptotic cells by flow cytometry or fluorescence microscopy. When combined with a membrane-impermeant DNA-binding dye (e. g. , propidium iodide), this approach allows discrimination between viable (Annexin V−/dye−), early apoptotic (Annexin V+/dye−), and late apoptotic or necrotic (Annexin V+/dye+) cell populations by assessing membrane integrity and PS exposure.
-
Apoptosis Solutions
Apoptosis is a regulated, generally non-lytic cell-death pathway that removes unwanted, damaged, infected, or abnormal cells through coordinated morphological changes, caspase activation, DNA fragmentation, and membrane remodeling. The intrinsic apoptosis pathway is controlled mainly by mitochondrial outer membrane permeabilization, BCL-2 family proteins, cytochrome c release, apoptosome formation, caspase-9 activation, and downstream executioner caspase-3/7 activation. The extrinsic apoptosis pathway is initiated by death receptors such as Fas, TNFR, and TRAIL receptors, which recruit adaptor proteins and activate caspase-8 before engaging executioner caspases or mitochondrial amplification through BID cleavage. Apoptosis is linked to many phenotypes, including cancer cell killing, tissue homeostasis, immune regulation, neurodegeneration, infection response, and treatment-induced cytotoxicity; unresolved questions include how apoptosis interacts with necroptosis, pyroptosis, ferroptos
-
Breast Cancer Modeling
Breast cancer is a heterogeneous cancer, and it has been distinguished into four subtypes: luminal A, luminal B, HER2-positive and basal-like. Molecular mutations, epigenetic alterations, hormone exposure and immune microenvironment are related to the progression of breast cancer.
-
Cell Viability Determination by MTT Colorimetric Assay
The following protocol uses the MTT colorimetric assay as a classic literature-established method for assessing cell viability/metabolic activity in cultured mammalian cells. MTT[3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide] is reduced by metabolically active cells to a colored formazan product; the amount of formazan is quantified spectrophotometrically and provides an indirect measure of metabolically active viable cells. Importantly, MTT reduction reflects cellular oxidoreductase/metabolic activity rather than an absolute direct count of living cells, so changes in cellular metabolism can alter the signal independently of cell number.
Pureza y Documentación
-
Ficha de datos (321 KB)
-
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
-
Instrucciones de manejo (2659 KB)
Referencias
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)